The effectiveness of daily versus intermittent oral iron supplementation in pregnancy: A randomized controlled trial

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230310002

Enrollment

Registered

2023-03-10

Start date

2023-02-22

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anemia in pregnancy anemia pregnancy iron supplement intermittent iodine

Interventions

triferdine 1 tab daily ,intermittent triferdine 1 tab EOD, triferdine1 tab plus ferrous fumarate 1 tab weekly

Active Comparator Drug,Active Comparator Drug,Experimental Drug

daily iron,intermittent iron,weekly iron

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. BMI more than 18.5 2. GA less than 20 week 3. no anemia 4. no history of thyroid disease and iodine deficiency

Exclusion criteria

Exclusion criteria: 1. history of hematological disease 2. history of malabsorption and gi disease 3. history of Bariatric surgery 4. preterm labour, PPROM, sign of infection

Design outcomes

Primary

Measure	Time frame
hemoglobin GA 32-36 week g/dl	—

Secondary

Measure	Time frame
iodine GA 32-36 weeks microgram/L	—

Countries

Thailand

Contacts

Public ContactPornsak Thirathanaboon

Somdejprasangkharaj 17 Hospital

pornsak091012@gmail.com0898878251

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026